110 results
Page 2 of 6
8-K
EX-99.1
nwxzb
9 Aug 22
Ovid Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
8:18am
8-K
EX-99.1
c4m 3p4e84id
10 May 22
Ovid Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights
8:05am
8-K
EX-10.1
7gr6afdg6
3 Jan 22
Entry into a Material Definitive Agreement
7:00am
8-K
EX-99.1
dvq21veubeu1n1n x2n
19 Apr 21
OVID Provides Update on OV101 Program and the Prioritization of its Resources
8:31am
8-K
EX-99.1
3n858brzvd
9 Apr 21
Regulation FD Disclosure
10:01am
8-K
EX-99.1
xqv25uls
1 Dec 20
Ovid Therapeutics Announces Phase 3 NEPTUNE Clinical Trial of OV101 for the Treatment of Angelman Syndrome Did Not Meet Primary Endpoint
5:19pm
424B5
l32c7r0 i9lphassi5
20 Nov 20
Prospectus supplement for primary offering
4:23pm
8-K
EX-99.1
jlzy dvqn1mvnwmpw
12 Nov 20
Ovid Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
4:28pm